Cargando…

Blood Targets of Adjuvant Drugs Against COVID19

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-k...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Micco, Pierpaolo, Di Micco, Gianluca, Russo, Vincenzo, Poggiano, Maria Rita, Salzano, Ciro, Bosevski, Marijan, Imparato, Michele, Fontanella, Luca, Fontanella, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338832/
https://www.ncbi.nlm.nih.gov/pubmed/32694923
http://dx.doi.org/10.2147/JBM.S256121
Descripción
Sumario:While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.